Literature DB >> 21180621

A review of the use of zonisamide in Parkinson's disease.

Pedro Emilio Bermejo1, Buenaventura Anciones.   

Abstract

Although zonisamide was previously only used to treat epilepsy, recently more applications have been forthcoming. Due to a good side effect profile, a lower frequency of interactions and a more comfortable posology, there are several studies regarding its uses in other pathologies such as migraine, neuropathic pain, essential tremor and various psychiatric diseases. A multicentered, randomized, double-blind, placebo-controlled study conducted in Japan suggested that zonisamide, as an add-on treatment, has efficacy in treating motor symptoms in patients with Parkinson's disease. In addition, other studies support the utility of zonisamide in other symptoms of this disease. The therapeutic doses of zonisamide for the treatment of Parkinson's disease are considerably lower than those for the treatment of epilepsy. This antiepileptic drug has been used in Japan for more than 15 years and so it is expected that it will be safe and well tolerated in patients with Parkinson's disease. However, the pharmacological mechanisms of the antiparkinsonian actions of zonisamide remain unclear and more basic investigation is warranted. The aim of this paper is to review the structure, mechanisms of action, pharmacokinetics and antiparkinsonian action of zonisamide.

Entities:  

Keywords:  Parkinson's disease; antiepileptic; neuromodulator; zonisamide

Year:  2009        PMID: 21180621      PMCID: PMC3002602          DOI: 10.1177/1756285609338501

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN: 1756-2856            Impact factor:   6.570


  30 in total

Review 1.  An update on the treatment of Parkinson's disease.

Authors:  Joseph Jankovic
Journal:  Mt Sinai J Med       Date:  2006-07

2.  [Role of antiepileptic drugs in Parkinson's disease].

Authors:  Pedro Emilio Bermejo; José María Gómez-Argüelles; Juan Manuel Sepúlveda
Journal:  Med Clin (Barc)       Date:  2008-10-11       Impact factor: 1.725

3.  Zonisamide has beneficial effects on Parkinson's disease patients.

Authors:  M Murata; E Horiuchi; I Kanazawa
Journal:  Neurosci Res       Date:  2001-12       Impact factor: 3.304

4.  A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Authors:  Theresa A Zesiewicz; Christopher L Ward; Robert A Hauser; Juan Sanchez-Ramos; Joseph F Staffetti; Kelly L Sullivan
Journal:  Mov Disord       Date:  2007-01-15       Impact factor: 10.338

5.  Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol.

Authors:  Shuhei Morita; Hideto Miwa; Tomoyoshi Kondo
Journal:  Parkinsonism Relat Disord       Date:  2005-03       Impact factor: 4.891

Review 6.  Fatigue in Parkinson's disease: a review.

Authors:  Joseph H Friedman; Richard G Brown; Cynthia Comella; Carol E Garber; Lauren B Krupp; Jau-Shin Lou; Laura Marsh; Lillian Nail; Lisa Shulman; C Barr Taylor
Journal:  Mov Disord       Date:  2007-02-15       Impact factor: 10.338

Review 7.  Oxcarbazepine, topiramate, zonisamide, and levetiracetam: potential use in neuropathic pain.

Authors:  David R P Guay
Journal:  Am J Geriatr Pharmacother       Date:  2003-09

Review 8.  Clinical pharmacology and mechanism of action of zonisamide.

Authors:  Victor Biton
Journal:  Clin Neuropharmacol       Date:  2007 Jul-Aug       Impact factor: 1.592

9.  Restless legs syndrome in Parkinson's disease.

Authors:  Juan C Gómez-Esteban; Juan J Zarranz; Beatriz Tijero; Fernando Velasco; Joseba Barcena; Idoia Rouco; Elena Lezcano; María C Lachen; Amaia Jauregui; Amaia Ugarte
Journal:  Mov Disord       Date:  2007-10-15       Impact factor: 10.338

10.  Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.

Authors:  M R Gluck; L A Santana; H Granson; M D Yahr
Journal:  J Neural Transm (Vienna)       Date:  2004-04-08       Impact factor: 3.575

View more
  6 in total

1.  Zonisamide in managing impulse control disorders in Parkinson's disease.

Authors:  Pedro Emilio Bermejo; Cristina Ruiz-Huete; Buenaventura Anciones
Journal:  J Neurol       Date:  2010-05-28       Impact factor: 4.849

2.  Update on treatment of essential tremor.

Authors:  Theresa A Zesiewicz; Jessica D Shaw; Kevin G Allison; Joseph S Staffetti; Michael S Okun; Kelly L Sullivan
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

Review 3.  Emerging role of S100B protein implication in Parkinson's disease pathogenesis.

Authors:  Efthalia Angelopoulou; Yam Nath Paudel; Christina Piperi
Journal:  Cell Mol Life Sci       Date:  2020-10-14       Impact factor: 9.261

4.  Single Administration of the T-Type Calcium Channel Enhancer SAK3 Reduces Oxidative Stress and Improves Cognition in Olfactory Bulbectomized Mice.

Authors:  Dian Yuan; An Cheng; Ichiro Kawahata; Hisanao Izumi; Jing Xu; Kohji Fukunaga
Journal:  Int J Mol Sci       Date:  2021-01-13       Impact factor: 5.923

5.  Excitatory deep brain stimulation quenches beta oscillations arising in a computational model of the subthalamo-pallidal loop.

Authors:  Seyed Mojtaba Alavi; Amin Mirzaei; Alireza Valizadeh; Reza Ebrahimpour
Journal:  Sci Rep       Date:  2022-05-12       Impact factor: 4.996

Review 6.  Old Drugs as New Treatments for Neurodegenerative Diseases.

Authors:  Fernando Durães; Madalena Pinto; Emília Sousa
Journal:  Pharmaceuticals (Basel)       Date:  2018-05-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.